- Home
- MRSH vs BMY Comparison
MRSH vs BMY Comparison
Compare MRSH & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRSH | BMY |
|---|---|---|
| Founded | 1871 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.3B | 113.5B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MRSH | BMY |
|---|---|---|
| Price | $192.20 | $67.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $199.27 | $61.73 |
| AVG Volume (30 Days) | 2.1M | ★ 11.8M |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | 2.11% | ★ 4.38% |
| EPS Growth | 3.06 | ★ 178.46 |
| EPS | ★ 4.99 | 2.93 |
| Revenue | $26,981,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | $38.11 | ★ $22.37 |
| Revenue Growth | ★ 10.32 | N/A |
| 52 Week Low | $156.60 | $42.52 |
| 52 Week High | $198.49 | $68.64 |
Technical Indicators
Market Signals| Indicator | MRSH | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 63.92 |
| Support Level | $175.14 | $56.46 |
| Resistance Level | $193.32 | $68.10 |
| Average True Range (ATR) | 3.43 | 1.59 |
| MACD | -0.68 | 0.03 |
| Stochastic Oscillator | 80.42 | 75.62 |
Price Performance
Historical ComparisonAbout MRSH Marsh Common Stock
Marsh is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.